


HAW/SB

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number Filing Date First Named Inventor Art Unit Examiner Name Total Number of Pages in This Submission	10/705,282 11/10/2003 Chackalamannil 1625 To Be Assigned 10 CV01185K1X
--	--

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CID	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
PTO Form 1449 (3 pages); References (53 documents); Post Card		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Schering-Plough Corporation.		
Signature			
Printed name	Gerard E. Reinhardt		
Date	June 08, 2005	Reg. No.	43,041


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name			
	Date		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer U S Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED I TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Chackalamannil, S., et.al.

Group Art Unit: 1625

Application No.: 10/705,282

Examiner: To Be Assigned

Filed: November 10, 2003

Attorney Docket No. : CV01185K1X

For: Methods of Use of
Thrombin Receptor Antagonists

X

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

(a) Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Form PTO-1449 be considered and made of record in the above-identified patent application. Other than cited U.S. patents and published patent applications, copy(ies) of these documents are enclosed were filed in related U.S. Application No(s) 10/705,282 filed November 10, 2003, respectively. Since the Examiner is believed to have ready access to the cited U.S. patents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

(b) No fee is believed to be due because:

- This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; or
- This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; or
- This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); or
- This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:

- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or


06/09/2005 FMETEK11 00000087 190365 10705282

01 FC:1806 180.00 DA

- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; or
 - The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- (d) This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and:
- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
 - No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; and
 - The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365. A DUPLICATE COPY OF THIS SHEET IS ENCLOSED.


Dated: June 8, 2005
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

Respectfully submitted,

By: 
Gerard E. Reinhardt
Reg. No.: 43,041
Attorney of Record
Telephone No.: (908) 298-2960

Express Mail Label: EV 533188599 US

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number



Effective on 1210812004.
Fees pursuant to the *Consolidated Appropriations Act, 2005* (H.R. 4818).

FEE TRANSMITTAL

For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)
180.00

Complete if Known

Application Number	10/705,282
Filing Date	11/10/2003
First Named Inventor	Chackalamannil
Examiner Name	To Be Assigned
Art Unit	1625
Attorney Docket No.	CV01185K1X

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____
 Deposit Account Deposit Account Number: 19-0365 Deposit Account Name: Schering-Plough Corporation.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for *the filing fee*
 Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments
 under 37 CFR 1.16 and 1.17

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

<u>Application Typ</u>	<u>Filing Fees</u>	<u>SEARCH FEES</u>	<u>EXAMINATION FEES</u>	<u>Fees Paid (\$)</u>
utility	300	500	200	_____
Design	200	100	130	_____
Plant	200	300	160	_____
Reissue	300	500	600	_____
Provisional	200	0	0	_____

2. EXCESS CLAIM FEES

Fee Description Fee (\$)
 Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent 50
 Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent 200
 Multiple dependent claims 360

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
- 20 or HP =	x	-	-			
HIP = highest number of total claims paid for, if greater than 20						

Indep. Claims Extra Claims Fee (\$) Fee Paid (\$)
 - 3 or HP = x -

HIP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEEIf the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity)
for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41 (a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof Fee (\$)</u>	<u>Fee Paid (\$)</u>
- 100=	/50=	(round up to a whole number) x	_____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Information Disclosure Statement

180.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent) 43,041	Telephone 908-298-2960
Name (Print/Type)	Gerard E. Reinhardt	Date	June 08, 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FORM PTO-1469 PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01185K1X	SERIAL NO.: 10/705,282
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT: Chackalamannil, S.	
		FILING DATE: 11/10/2003	GROUP: 1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA	6,063,847	05/16/00				
AB	6,326,380 B1	12/04/01				
AC	6,645,987	11/11/03				
AD	6,894,065	05/17/05				
AE	03/0216437	11/20/03				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO
AF	WO/9926943 A	06/03/99					
AG	WO/0196330 A	12/20/01					
AH	Invitation to pay additional fees	06/05/05					
AI							
AJ							

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

AK	Ahn, Ho-Sam, et.al. "Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases", CURRENT PHARMACEUTICAL DESIGN, Vol. 9 (28) pp. 2349 – 2365, (2003).
AL	Asanuma, Kunihiro, et.al. "Thrombin Inhibitor, Argatroban, Prevents Tumor Cell Migration and Bone Metastasis", ONCOLOGY, Vol. 67(2), pp. 166 – 173, (2004).
AM	Asokanathan, Nithianthan, et.al. "Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells", JOURNAL OF IMMUNOLOGY, Vol. 168 (7), pp. 3577 – 3585, (2002).
AN	Barrios, Victor, et.al. "Proteinase-activated receptor-2 mediates hyperresponsiveness in isolated guinea pig bronchi.", BIOCHEMICAL PHARMACOLOGY, Vol. 66 (3), pp. 519-525, (2003).
AO	Buresi, M.C., et.al. "Protease-activated receptor-1 stimulates Ca ²⁺ -dependent Cl- secretion in human intestinal epithelial cells", AMERICAN JOURNAL OF PHYSIOLOGY- GASTRO INTEST LIVER PHYSIOL Vol. 281 (2, Pt. 1), G323-G332, (2001)
AP	Copple, Bryan, L., et. al. "Thrombin and protease-activated receptor-1 agonists promote lipopolysaccharide-induced hepatocellular injury in perfused livers", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol. 305 (2), pp. 417 – 425, (2003)
AQ	Chambers, R.C.,et.al. "Coagulation cascade proteases and tissue fibrosis", BIOCHEMICAL SOCIETY TRANSACTIONS, Vol. 30 (2), pp. 194 – 200, (2002).
AR	Chambers, R.C., "Proteinase-activated receptors and the pathophysiology of pulmonary fibrosis", DRUG DEVELOPMENT RESEARCH, Vol. 60(1), pp. 29-35, (2003).
AS	Coughlin, S., et.al. "PARticipation in inflammation. JOURNAL OF CLINICAL INVESTIGATION, 111(1), pp. 25-27, (2003).
AT	D'Andrea, M. et.al., "Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder", AMERICAN JOURNAL OF PATHOLOGY, Vol. 162(3), pp. 907-923, (2003).
AU	Darmoul, Dalila, et.al., "Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation", MOLECULAR CANCER RESEARCH, Vol. 2(9), pp. 514-522, (2004).
AV	Derian, Claudia, et.al., "Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opinion on Investigational Drugs Vol. 12(2), 209-221, (2003).
AW	Even-Ram, Sharona, et. al., "The pattern of expression of protease-activated receptors (PARs) during early trophoblast development", JOURNAL OF PATHOLOGY, Vol. 200(1), pp. 47-52, (2003).

	AX	Even-Ram, Sharona, et. al., "Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the av β 5 integrin", JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 276(14), pp.10952-10962, (2001).
	AY	Feistritzer, Clemens, et.al., "Thrombin Affects Eosinophil Migration via Protease-Activated Receptor-1", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, Vol. 135 (1), 12-16, (2004).
	AZ	Ferroni, P., et.al., "Platelet activation in type 2 diabetes mellitus" JOURNAL OF THROMBOSIS AND HAEMOSTASIS Vol. 2(8), pp. 1282-1291, (2004).
	BA	Flynn, A.N., et.al., "Proteinase-activated receptor 1 (PAR-1) and cell apoptosis" APOPTOSIS, Vol. 9(6), pp. 729-737, (2004).
	BB	Fiorucci, Stefano, et.al., "PAR1 antagonism protects against experimental liver fibrosis.Role of proteinase receptors in stellate cell activation" HEPATOLOGY, Vol. 39(2), pp. 365-375 (2004).
	BC	Fortini, Mark, "PAR-1 for the course of neurodegeneration" CELL Vol. 116(5), pp. 631-632, (2004).
	BD	Gabazza, Esteban C, "Progress in the understanding of protease-activated receptors", INTERNATIONAL JOURNAL OF HEMATOLOGY, Vol. 79(2), pp.117-122, (2004).
	BE	Gaca, Marianna, et.al. "Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors" JOURNAL OF HEPATOLOGY, Vol. 36(3), pp. 362-369, (2002).
	BF	Hauck, R.W, et.al. "Alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors" AMERICAN JOURNAL OF PHYSIOLOGY, Vol. 277(1, Pt. 1), L22-L29, (1999).
	BG	Howell, D.C.,et.al. "Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis" AMERICAN JOURNAL OF PATHOLOGY Vol. 159(4), pp. 1383-95, (2001).
	BH	Jin, Enjing, et.al. "Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas". CANCER Vol. 97(3), pp. 703-713. (2003).
	BI	Jurasz, Paul, et.al. "Platelet-cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation" BRITISH JOURNAL OF PHARMACOLOGY, Vol. 143(7), pp. 819-826, (2004).
	BJ	Kawabata, Atsufumi "Gastrointestinal functions of proteinase-activated receptors" LIFE SCIENCES, Vol. 74(2-3), pp. 247-254, (2003).
	BK	Kuroda, Ryotaro, et.al. "Pain information pathways from the periphery to the cerebral cortex" Yakugaku Zasshi, Vol. 123(7), pp. 533-546, (2003).
	BL	Lan, Rommel, et.al. "Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice" AMERICAN JOURNAL OF PHYSIOLOGY: LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, Vol. 286(2), L388-98, (2004).
	BM	Liu, Jian, et.al. "Expression of functional protease-activated receptor 1 in human prostate cancer cell lines" UROLOGICAL RESEARCH Vol. 31(3), pp. 163-168, (2003).
	BN	Liu, Y., et.al. "Expression of protease-activated receptor 1 in oral squamous cell carcinoma" CANCER LETTERS Vol. 169(2), pp. 173-180, (2001).
	BO	Moffatt, James, et.al. "Effects of inhaled thrombin receptor agonists in mice" British Journal of Pharmacology Vol. 143(2), pp. 269-275 (2004).
	BP	Miyata, Satoshi, et.al. "Trypsin stimulates integrin α 5 β 1-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2" JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 275(7), pp. 4592-4598, (2000).
	BQ	Nierodzik, M. L., et.al. "Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis" BLOOD Vol. 92(10), pp. 3694-700, (1998).
	BR	Rattenholl, Anke, et.al. "Role of proteinase-activated receptors in cutaneous biology and disease" DRUG DEVELOPMENT RESEARCH Vol. 59(4), pp. 408-416, (2003).
	BS	Reed, Charles, et. al. "The role of protease activation of inflammation in allergic respiratory diseases" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol. 114(5), 997-1008, (2004).
	BT	Reiter, Rosemarie, et.al. "Regulation of protease-activated receptor I (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans" THROMBOSIS AND HAEMOSTASIS Vol. 90(5), 898-903 (2003).
	BU	Robey, R.B., et.al. "Thrombin is a novel regulator of hexokinase activity in mesangial cells" KIDNEY INTERNATIONAL Vol. 57(6), pp. 2308-18. Journal code: 0323470, (2000)
	BV	Roche, Nicholas, et. al. "Effect of acute and chronic inflammatory stimuli on expression of protease-activated receptors 1 and 2 alveolar macrophages. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY Vol. 111(2), pp. 367-373, (2003).

	BW	Rohatgi, Tanuja, et.al. "Protease-Activated Receptors in Neuronal Development, Neurodegeneration, and Neuroprotection: Thrombin as Signaling Molecule in the Brain", THE NEUROSCIENTIST, Vol 10 (6), pp. 501 – 512, (2004).
	BX	Ruf, W., et.al. "Specificity of coagulation factor signaling" JOURNAL OF THROMBOSIS AND HAEMOSTASIS Vol. 1(7), pp. 1495-1503, (2003).
	BY	Sekiguchi, Fumiko, et.al. "Protease-activated receptors (PARs) as therapeutic targets: Development of agonists/antagonists and modulation of gastrointestinal functions" DRUG DESIGN REVIEWS – Online Vol. 1(4), pp. 287-296, (2004).
	BZ	Shi, Xiaoli, et.al. "Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis" MOLECULAR CANCER RESEARCH Vol. 2(7), 395-402, (2004).
	CA	Shimizu, Tadamichi, et.al. "Macrophage Migration Inhibitory Factor Is Induced by Thrombin and Factor Xa in Endothelial Cells" JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279(14), pp. 13729-13737, (2004).
	CB	Thamboo, T. P., et. al. "Hep Par 1 expression in carcinoma of the cervix: Implications for diagnosis and prognosis" JOURNAL OF CLINICAL PATHOLOGY Vol. 57(1), 48-53, (2004).
	CC	Tran, Thai, et. al. "Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle" British Journal of Pharmacology 138(5), 865-875, (2003).
	CD	Vergnolle, Nathalie, et.al. "A role for proteinase-activated receptor-1 in inflammatory bowel diseases", JOURNAL OF CLINICAL INVESTIGATION Vol. 114(10), 1444-56 (2004).
	CE	Villari, D., et.al. "Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study" PATHOLOGY Vol. 34(5), pp. 423-426, (2002).
	CF	Wang, Junru, et.al. "Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: Possible link between endothelial dysfunction and chronic radiation fibrosis" AMERICAN JOURNAL OF PATHOLOGY Vol. 160(6), 2063-2072, (2002).
	CG	Yin, Yong-Jun, et.al. "Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB JOURNAL Vol. 17(2), pp. 163-174, (2003).
	CH	Yuan Ta Chun, et.al."Protease-activated receptor 1: a role in prostate cancer metastasis" CLINICAL PROSTATE CANCER Vol. 3(3), pp. 189-91, (2004).
	CI	Zhang, Xin, et.al. "Correlation of Protease-Activated Receptor-1 With Differentiation Markers in Squamous Cell Carcinoma of the Head and Neck and Its Implication in Lymph Node Metastasis. CLINICAL CANCER RESEARCH Vol. 10(24), pp. 8451-8459, (2004).
	CJ	
	CK	
	CL	
	CM	
	CN	
EXAMINERA		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

53157_1